Thema: US5560991094
MGNX, US5560991094
stock-5051155_1920.jpg - Foto: THN
MacroGenics stock: MGC026 data support new combination study
MacroGenics stock received positive interim data for its MGC026 antibody-drug conjugate. The company plans a front-line combination study with pembrolizumab.
ad-hoc-news.de, heute 00:42 Uhr
MGNX, US5560991094
MacroGenics starts MGC030 trial. MacroGenics stock sits ...
Second-quarter revenue was USD 32.83 million versus USD 59.14 million expected. MacroGenics stock costs EUR 3.13 on October 20, 2026 at 7:08 p.m. CEST.
ad-hoc-news.de, 20.10.26 19:15 Uhr
MGNX, US5560991094
Six brokers set USD 6.33 target for MacroGenics stock
The 52-week range is USD 1.29 to USD 5.08. MacroGenics stock last traded at USD 3.25 on October 16, down 3.56 percent versus the Nasdaq prior close of USD 3.37.
ad-hoc-news.de, 17.10.26 21:15 Uhr
MGNX, US5560991094
MacroGenics stock has October 23 data ahead in 2026
Second-quarter revenue was USD 32.83 million on August 13, 2026. MacroGenics stock costs EUR 3.00 on October 15, 2026 at 10:54 p.m. CEST.
ad-hoc-news.de, 15.10.26 22:56 Uhr
MGNX, US5560991094
MacroGenics insider exercises 8,000 options for MacroGenics ...
MacroGenics stock costs EUR 3.16 on October 8, 2026 after EUR 3.17, minus 0.32 percent. Second-quarter revenue reached USD 32.80 million.
ad-hoc-news.de, 08.10.26 14:10 Uhr
MGNX, US5560991094
MacroGenics stock fell 2.47 percent on October 7 with pipeline ...
MacroGenics stock closed at USD 3.55 on October 7, 2026, with market capitalization at USD 225.6 million. Q2 revenue rose to USD 32.8 million.
ad-hoc-news.de, 08.10.26 00:35 Uhr
MGNX, US5560991094
MacroGenics reports revenue miss and gets USD 6.33 target ...
